Ann: March 2025 Quarterly Activities Report & Appendix 4C, page-4

I think the market is totally overlooking the quality of this partnership with Sandoz.
Sandoz is doing majority of the heavy lifting here, clearly they see significant potential in the clinical outcome and market potential.
Re-reading this again really gives me a sense of confidence, if we can get some more deals inked before read-out, that will further help cement confidence..

"Under the terms of the agreement, Sandoz paid Avecho an upfront licensing fee of US$3M (approx.
A$4.8M) for the exclusive commercial rights to the CBD product for insomnia in Australia for a period
of ten years, with a first right of refusal to additional international territories. Avecho will continue to
fund and oversee the ongoing Phase III clinical trial. Upon successful completion, Avecho and Sandoz
will collaborate to secure TGA regulatory approval. Sandoz will purchase finished product from Avecho
and assume responsibility for the product's commercialisation, including marketing and distribution in
Australia. Avecho is eligible for development milestone payments totalling US$16M prior to
commercialisation and will receive tiered royalties ranging from 14% to 19% on net sales once on
market."